Biogen News and Research

RSS

Ohio State University Wexner Medical Center administers first targeted gene therapy for ALS

The Ohio State University Wexner Medical Center is one of the first nationwide to administer a targeted gene therapy for patients with a specific form of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that affects the cells in the brain and spine.

8 Sep 2023

Higher educational attainment may have a protective effect against Alzheimer's in people with genetic risk

A new study by researchers from Mass General Brigham further illustrates that when it comes to risk of Alzheimer's disease, even genetically determined forms of the disease, genetics is only one piece of the puzzle.

30 Aug 2023

Football players at increased risk for Parkinson's disease, study finds

Identification of risk factors for Parkinson's disease (PD) is essential for early diagnosis. Dating back to the 1920s, Parkinson's disease and parkinsonism-;an umbrella term that refers to motor symptoms found in Parkinson's disease and also other conditions-;have long been described in boxers.

11 Aug 2023

Less than half of approved new drugs add substantial therapeutic value over existing treatments

New drugs are often used not only for one disease (first approved indication) but also for other diseases (supplemental indications).

5 Jul 2023

Study finds the risk of recurrence of active disease in older patients with MS after discontinuing therapy

An article published today in the journal Lancet Neurology evaluates the risk of recurrence of active disease in older patients with multiple sclerosis after discontinuing disease-modifying therapies.

23 Jun 2023

Study finds altered gut bacteria in people with early signs of Alzheimer's disease

People in the earliest stage of Alzheimer's disease -; after brain changes have begun but before cognitive symptoms become apparent -; harbor an assortment of bacteria in their intestines that differs from the gut bacteria of healthy people, according to a study by researchers at Washington University School of Medicine in St. Louis.

14 Jun 2023

Phone menu test assesses daily functioning in people at risk of developing Alzheimer's disease

A new study by investigators from Mass General Brigham has found that a brief, simulated task of navigating a phone menu can detect the earliest changes in daily functioning in people at risk of developing Alzheimer's disease.

14 Jun 2023

This panel will decide whose medicine to make affordable. Its choice will be tricky.

Catherine Reitzel's multiple sclerosis medication costs nearly $100,000 a year. Kris Garcia relies on a drug for a blood-clotting disorder that runs $10,000 for a three-day supply. And Mariana Marquez-Farmer would likely die within days without her monthly $300 vial of insulin.

25 May 2023

Targeting mucus plugs could help prevent deaths from COPD, study suggests

A retrospective analysis of patient data from the COPDGene study suggests that targeting mucus plugs could help prevent deaths from chronic obstructive pulmonary disease-;the fourth leading cause of death in the United States.

22 May 2023

The role of RNA splicing in one of the deadliest forms of pancreatic cancer

In this interview, we spoke to Adrian Krainer, a Professor at Cold Spring Harbor Laboratory, about his latest research into the role of RNA splicing in one of the deadliest forms of pancreatic cancer.

22 May 2023

Newly identified genetic variant provides protection from Alzheimer's disease

A single patient can spark new research questions and provide answers about a disease. And when a new case is identified, investigators can make connections between them that can lead to even more powerful and persuasive ideas about cause and treatment.

15 May 2023

Higher exposure to fine particulate pollution may raise dementia risk

Exposure to fine particulate matter (PM2.5) air pollution is linked to a heightened risk of dementia, even at levels below current US, UK and European air quality standards, finds research published by The BMJ.

6 Apr 2023

Air pollution associated with increased risk of developing dementia

Exposure to fine particulate air pollutants (PM2.5) may increase the risk of developing dementia, according to a new meta-analysis from Harvard T.H. Chan School of Public Health.

6 Apr 2023

Quanterix’s Simoa® technology drives advances in Alzheimer’s disease research presented at 2022 Clinical Trials On Alzheimer’s Disease (CTAD) conference

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from November 29 to December 2, 2022.

From Quanterix 12 Dec 2022

The business of clinical trials is booming. Private equity has taken notice.

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.

2 Dec 2022

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

30 Nov 2022

Biogen News and Research

Ohio State University Wexner Medical Center administers first targeted gene therapy for ALS

Higher educational attainment may have a protective effect against Alzheimer's in people with genetic risk

Football players at increased risk for Parkinson's disease, study finds

Less than half of approved new drugs add substantial therapeutic value over existing treatments

Study finds the risk of recurrence of active disease in older patients with MS after discontinuing therapy

Study finds altered gut bacteria in people with early signs of Alzheimer's disease

Phone menu test assesses daily functioning in people at risk of developing Alzheimer's disease

This panel will decide whose medicine to make affordable. Its choice will be tricky.

Targeting mucus plugs could help prevent deaths from COPD, study suggests

The role of RNA splicing in one of the deadliest forms of pancreatic cancer

Newly identified genetic variant provides protection from Alzheimer's disease

Higher exposure to fine particulate pollution may raise dementia risk

Air pollution associated with increased risk of developing dementia

Quanterix’s Simoa® technology drives advances in Alzheimer’s disease research presented at 2022 Clinical Trials On Alzheimer’s Disease (CTAD) conference

The business of clinical trials is booming. Private equity has taken notice.

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

New Community of Experts launched to harness social media data for patient-centric drug development

Amyloid-PET scanning has misled the FDA into granting approval for Aduhelm

Decline in specific protein levels linked to Alzheimer’s disease, not buildup of amyloid plaques

New genetically-targeted MND therapy could be a turning point for patient care

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News